LANSING – As part of an international court settlement, Michigan will get more than $1.6 million in a case where the U.S. subsidiary of an Irish company was charged with improperly promoting its drugs approved to treat attention deficit hyperactivity disorder to also treat ulcerative colitis.
The settlement affects Shire Pharmaceuticals of Pennsylvania, which is a subsidiary of Shire Pharmaceuticals of Ireland, and it involves marketing the firm did for the ADHD drugs of Adderall XR, Vyvanse, Daytranam Lialda and Pentasa for mild to moderate ulcerative colitis.
Schuette directed that the $1.67 million the state will receive go to the state’s Medicaid program.
The entire settlement with the U.S. and states involved in the suit was for $56.5 million, with most of that going to Medicaid programs. Schuette said this was the first global settlement that reimbursed states like Michigan that provide drugs to Medicaid patients through managed care programs.
This story was provided by Gongwer News Service. To subscribe, click on Gongwer.Com
